tracken
Madrigal Pharmaceuticals, Inc. Aktie News
Neutral
GlobeNewsWire
●
6 Tage alt
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 15, 2025 to three new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 I...
Neutral
Seeking Alpha
●
6 Tage alt
Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Divisio...
Neutral
GlobeNewsWire
●
9 Tage alt
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Neutral
GlobeNewsWire
●
16 Tage alt
Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatment New analysis examining effects of Rezdiffra trea...
Neutral
GlobeNewsWire
●
20 Tage alt
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induc...
Neutral
Seeking Alpha
●
22 Tage alt
Madrigal Pharmaceuticals, Inc. ( MDGL ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Tina Ventura - Chief Investor Relations Officer William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer ...
Neutral
GlobeNewsWire
●
22 Tage alt
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, re...
Positiv
Market Watch
●
23 Tage alt
The volatile sector is seeing greater stability, and these four stocks can profit.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
